65,437 trials
Posttraumatic Stress Disorder
Primary: Change From Baseline to Primary Endpoint in Clinician Administered PTSD Scale for DSM-V (CAPS-5) — -23.69; -14.78 score on a scale
Dry Eye
Primary: Mean Ocular Surface Staining From Baseline — 0.8; 0.6; 0.5; 0.9 Score on a scale
Deep Vein Thrombosis · Venous Thromboembolism
Primary: Pharmacokinetic Parameter of Apparent Systemic Clearance (CL/F) — 42.9 L/h
Air Pollution
Primary: Concentrations of M1 and M2 Macrophages in the Sputum 24 Hours After Exposure. — 6.823; 1.367 ratio of M2 to M1 macrophages
Graft Versus Host Disease · Hematopoietic/Lymphoid Cancer
Primary: 12 Month Disease Free Survival Probability — 51.8 percentage of participants
Fragile X Syndrome
Primary: Change in Weighted Child Intentional Communication Score — 0.14; 0.04 log10(scores on a scale) — p=0.1587
Wet Age-related Macular Degeneration · Neovascular Age-related Macular Degeneration
Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) — 5.5; 5.9 Letters correctly read
Fistula · Abdominal Injury · Negative Pressure Wound Therapy
Primary: Change in Inpatient Participant Pain Rating
Pharmacodynamic Response to Small Doses of Insulin
Primary: Postprandial Serum Glucose in mg/dL as a Response to Small Doses (0.075 to 0.15 IUs/Kg) Human Insulin Averaged Per Subject — 3.8; -1.8; 7 mg/dL — p=0.000016
COVID-19
Primary: Number of Participants With Sustained Recovery — 144; 136 Participants
Schizophrenia, Schizoaffective Disorder
Primary: Mean Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — 99.38; 98.54; 100.53; 100.03 Units on a scale — p=0.849
Alzheimer Disease
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0 Participants
Migraine
Primary: Long-term Safety of Chronic Intermittent Use of AXS-07 — 293; 118; 8; 10 Participants
Carpal Tunnel Syndrome
Primary: Change in Median Cold Detection Threshold (CDT) Post-acupuncture Compared to Pre-acupuncture When the Median Nerve is Treated — 0.73; -0.195; 0.865 JND (just noticeable…
Healthy Participant
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-07321332 — 2210; 1300 nanogram per milliliter (ng/mL) — p=0.05